KB-1291

Patritumab

52696

Home » Patritumab

Background of Patritumab

HER3, a member of the human epidermal growth factor receptor (HER) family, plays a unique and complex role in cancer biology and therapeutics. Patritumab, also known as U3-1287, is a fully human monoclonal antibody that targets the human epidermal growth factor receptor 3 (HER3). It functions by competitively inhibiting the binding of neuregulin (NRG) to HER3, which in turn leads to inhibited downstream signaling pathways that are implicated in cancer cell proliferation and survival.

Specifications

Catalog Number	KB-1291
Antibody Name	Patritumab
Isotype	Human IgG1, kappa
FC Muations	Wild Type
Target	HER3
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA \| FACS\| KD
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-354.
Zhang Q, Park E, Kani K, Landgraf R. Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in liganddependent signaling. Proc Natl Acad Sci USA 2012; 109: 13237-13242.
Jura N, Shan Y, Cao X, Shaw DE, Kuriyan J. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc Natl Acad Sci USA 2009; 106: 21608-21613.